Injective just gained a Wall Street doorway while Bitcoin and Ethereum slide. But XRP and TRON showed that an ETF launch can fizzle fast, so what would it take for INJ to turn this debut into a real breakout?
The Crypto Desk desk. Editor: Sam Daodu.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Injective (CRYPTO:INJ) trades at $8.11, up 5.2% over the past 24 hours. The uptick coincides with the launch of the first U.S. fund dedicated to staking the token. As a layer-1 blockchain, Injective serves as a foundational network similar to Ethereum (CRYPTO:ETH) and is designed for trading and finance applications.
Injective has had a strong year. After dropping to a low of $2.75 on April 2, 2026, the price surged to a high of $8.94 on October 20, 2026. Since the beginning of the year, Injective has gained 93%.
NASDAQ officially listed the Canary Staked INJ ETF (NASDAQ:INJC) effective today, as reported in a NASDAQ trader alert the day prior. Investors are now eyeing $20 as the next significant target for INJ. So is it feasible for INJ to reach $20 by 2027?
What INJ Would Be Worth at $20
With a circulating supply of 100 million tokens, a $20 price would imply a total market value of $2 billion. Currently, INJ is valued at around $811 million, positioning it as the 81st-largest cryptocurrency.
Supply dilution occurs when the number of tokens in circulation increases, meaning the same price point results in a higher market cap than in earlier cycles. For context, INJ’s all-time high was $52.62 on March 14, 2024. With the current token supply, reaching that previous high again would mean a market cap of $5.26 billion. INJ now trades 84.6% below that peak.
To reach $20, INJ would need to gain another 146.6% on top of the 93% it has already added this year. A second rally of this magnitude will likely require new buyers, and the ETF could be a key source of that demand.
Key Factors That Could Propel INJ Toward $20
ETF Capital Flows
An exchange-traded fund, or ETF, lets investors gain exposure to an asset through a standard brokerage account. Staking involves locking up tokens to help secure a network while earning rewards. The Canary fund aims to stake at least 90% of its INJ and charges an annual sponsor fee of 1.10%, working out to $11 a year for every $1,000 invested. Its Form 8-A filing shows NASDAQ approved the listing.
XRP’s first ETF launched with $250 million, yet its price fell 9%, a reminder that launching an ETF alone doesn’t guarantee a price increase. Canary’s TRON ETF faced the same test after its own launch.
On its first day, INJ’s gain was volatile. Initial reports indicated a 10% rise within 24 hours, before the gain shrank to 4.2% by mid-morning and climbed back to 5.2% by the afternoon. INJ was one of only three non-stable coins in the top 100 that gained value over this period, alongside Pearl and LEO Token, while most of the market declined.
It’s still early to assess inflow data. A listing can make buying easier, but it doesn’t ensure investors will actually buy. The first real indicators of demand will come with the fund’s weekly flow reports.
Strength Against a Weak Crypto Market
While the two biggest coins have fallen, INJ has risen. Since the beginning of the year, Bitcoin is down 8.1%, and Ethereum has dropped 18.5%. Bitcoin dominance, which measures its share of the total crypto market value, stands at 59.4%, meaning most of the market’s capital is still concentrated in Bitcoin.
Market sentiment remains neutral. The Fear and Greed Index, which gauges investor emotions on a scale from 0 to 100, shows a score of 48, while Bitcoin and Ethereum have slid further, down 4.8% and 6.8% over 24 hours. For INJ to reach a $2 billion valuation, Bitcoin will likely need to stabilize and stop its recent slide.
Injective ETF FAQ
What Is the Injective ETF?
The Canary fund holds INJ and stakes at least 90% of its holdings. Its shares trade on NASDAQ under the ticker INJC and carry a 1.10% annual fee.
What Is the Injective Price Prediction for 2027?
A few price scenarios are worth considering. A price of $10 would require a 23.3% gain, while $15 would require an 85% increase. Reaching $20 would take a 146.6% gain.
Will Injective Go Up Again?
INJ is currently trading above its 200-day moving average of $5.58. That average reflects the coin’s closing price over a set period, and trading above it often signals a potential uptrend. Even so, INJ still needs significant gains to return to its previous highs.
Can INJ Reach $20 by 2027?
The likelihood of INJ reaching $20 by the end of 2027 is low. The ETF offers a new entry point, but $20 would still require a 2.47x increase from the current price.
Several factors would need to align. INJ must break through its one-year high of $8.94 and then hold above $10, which would push its market value to $1 billion. The ETF’s flow reports also need to show steady buying while Bitcoin recovers from its losses for the year. The $10 level is the checkpoint to watch; a drop below $7.68 could send INJ back toward its 200-day average near $5.58.
Contact [email protected] for any questions or corrections.
Sam Daodu is a crypto analyst and the editor of 24/7 Wall St.'s Crypto Desk, where he covers Bitcoin, XRP, Ethereum, Solana and the altcoins investors search for most. His work focuses on price levels, spot ETF flows, on-chain data and the regulatory decisions that move crypto markets, written so a first-time buyer and a seasoned trader can both use it.
Sam has written about crypto professionally since 2019 and has published more than 2,000 articles. Before joining 24/7 Wall St., he wrote for crypto media outlets and Web3 companies and ghostwrote for crypto founders and token launches. His analysis is syndicated on Yahoo Finance, MSN and AOL and has been cited by other crypto news sites. He also founded MacLabs Marketing, a content and personal branding agency for crypto founders and executives.
When he isn't reading charts, Sam is usually at the gym or watching One Piece, a series he maintains has better tokenomics than most altcoins.
